Join to access to all OVN content. Join for Free
How and Why Medical Affairs Can Support Diversity in Clinical Trials
diversity in clinical trials role of MSLs FDA guidance on diversity patient-centric approaches cultural awareness and allyship

How and Why Medical Affairs Can Support Diversity in Clinical Trials


Share This Article


Summary

In this episode, Tom Caravela is joined by Brad Atkinson, Brian Wilson, and Christina Wright to explore the critical role of diversity in clinical trials and the MSL’s part in fostering inclusivity. The discussion covers FDA guidance on diversity, challenges in therapeutic areas, and the importance of patient-centric approaches. The speakers delve into the strategic roles of MSLs in education and the historical context of diversity in clinical trials. They provide actionable strategies for field medical teams to enhance trial diversity and emphasize the significance of cultural awareness and allyship. The episode concludes with reflections and a call to action for promoting diversity in medical settings.

Christina Wright, Brad Atkinson and Brian Wilson discuss the important role Medical Affairs/MSLs can play in supporting diversity in clinical trials

The group discusses…

👉 Why does medical affairs need to be involved in diversity clinical trial initiatives?

👉 How can field medical get comfortable with the D and I conversation?

👉 What resources can be helpful

👉 3 Pillars of “Allyship”

👉 Why insights are currency

Click for Source
diversity in clinical trials, role of MSLs, FDA guidance on diversity, patient-centric approaches, cultural awareness and allyship

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to create HIGH performing MSLs, teams and MSL leaders
Partner Avatar MSL Talk: Tom Caravela, Mike Penkethman

How to create HIGH performing MSLs, teams and MSL leaders

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Explore OVN